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Abstract
In our continuing search for natural product-based spin-labeled antitumor drugs, 20 novel spin-
labeled camptothecin derivatives were synthesized via a Cu-catalyzed one pot reaction and 
evaluated for cytotoxicity against four human tumor cell lines (A-549, MDA-MB-231, KB, and 
KBvin). Eighteen of the target compounds (9a, 9b, 9d–9k, 9m–9t) exhibited significant in vitro 
antiproliferative activity against these four tested tumor cell lines. Compounds 9e and 9j (IC50 
0.057 and 0.072 μM, respectively) displayed the greatest cytotoxicity against the multidrug-
resistant (MDR) KBvin cell line and merit further development into preclinical and clinical drug 
candidates for treating cancer including MDR phenotype.
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1. Introduction
Camptothecin (CPT, 1, Figure 1), a pentacyclic alkaloid isolated from Camptotheca 
acuminata by Wall et al., showed excellent antitumor activity against a broad spectrum of 
tumor cell lines by inhibiting topoisomerase I (Topo I).1–5 Two semisynthetic derivatives, 
topotecan (2) and irinotecan (3), are widely used clinically for treating ovarian and small-
cell lung cancers, respectively. Several other drug candidates, such as gimatecan (4), 
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CKD-602 (5), and BNP-1350 (6), are the subject of ongoing preclinical or clinical 
evaluation. 6–9
Although CPT analogues remain a promising class of antitumor agents, their therapeutic use 
has been severely hindered by toxicity issues and delivery problems, due to poor water 
solubility, as well as intrinsic instability of the highly electrophilic α-hydroxylactone of the 
E ring, due to preferential binding of the opened carboxylate to serum albumin.10,11 This 
chemical feature diminished efficacy of various CPT derivatives in vivo compared to the 
spectacular results often obtained from in vitro studies and xenograft models. Thus, several 
promising strategies to overcome this challenge have been developed. These approaches 
include the development of prodrugs (conjugates and polymer bound CPTs), new 
formulations (liposomes or microparticulate carriers), and synthetic lipophilic CPTs.12–14 
Most of these strategies aimed to maintain the active closed-lactone form in the plasma 
compartment, and encouraging results have been obtained. Additionally, extensive structure-
activity relationship (SAR) investigations have suggested that the intact lactone ring E of 
CPT is the most critical structural feature with respect to antitumor activity. A free 20-
hydroxy group favors lactone ring-opening due to formation of intra-molecular hydrogen 
bonding, while acylation of this group should render the lactone moiety more stable toward 
ring opening.15,16 Many studies have been focused on highly efficient semisynthetic 
methodologies paving the way for development of new potent C-20-modified CPT 
analogues. Indeed, our own results,17,18,19 as well as those of others with 20(S)-O-acyl 
esters,20,21 20(S)-O-carbonate linked tripeptide conjugates,22 and 20(S)-O-linked 
glycoconjugates,23 have supported the importance of esterified CPT derivatives for potent 
cytotoxic and antitumor activity. Esterification of the 20-hydroxyl group also enhances 
plasma stability compared with unmodified CPT, as well as augments in vivo superior 
antitumor activity without notable toxicities in liver, lung, kidney, and spleen.19
Furthermore, novel nitroxide-derived spin-labeling of antitumor drugs is a promising 
direction in anticancer chemotherapy, not only because these compounds exhibit superior 
cytotoxic activity, but also because they can be monitored by electron paramagnetic 
resonance (EPR) in pharmacological experiments. Based on current knowledge, the 
introduction of a stable nitroxyl radical into pharmaceutical molecules can reduce toxicity 
and potentiate antitumor effects to a certain degree. Some studies have shown that the 
introduction of a nitroxyl moiety can lead to fast decomposition, higher alkylating and lower 
carbamoylating activity, better anti-melanomic activity, lower general toxicity, and the 
ability to transport molecules through cell membranes, while the nitroxyl free radicals 
themselves possess low toxicity and are not mutagenic or carcinogenic.24–28 In our prior 
studies, we successfully prepared a number of spin-labeled derivatives of known antitumor 
agents, such as podophyllotoxin,29–36 CPT,37 rotenone,38 glycyrrhetinic acid,39 and 
combretastatin,40 resulting in compounds with superior pharmacological properties 
compared to those of the parent compounds. Inspired by this prior work, we herein report 
the design, synthesis, and in vitro cytotoxicity of a series of novel 20-modified spin-labeled 
CPT derivatives as part of our continuing search for promising natural product-derived 
anticancer agents.
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2. Results and discussion
2.1. Chemistry
The synthetic routes to target compounds are outlined in Scheme 1. Briefly, the 20-hydroxyl 
of CPT was esterified with various N-Boc-amino acid derivatives (7) in suitable yields by a 
simple modification of the carbodiimide method using a combination of N,N′-
diisopropylcarbodiimide (DIPC) and 4-dimethylaminopyridine (DMAP). Removal of the N-
Boc group of 7 with trifluoroacetic acid (TFA) in CH2Cl2 (1:1) formed the key intermediate 
TFA salts 8. Subsequently, these key precursors were successfully combined with 
sulfonylazides and alkynes in a Cu-catalyzed three-component reaction41 to afford the target 
compounds 9a–t in 59–75% yields. All newly synthesized compounds were purified by 
column chromatography and their structures were characterized by ESI-MS, EPR, IR, and 
elemental analysis.
2.2. Cytotoxicity
Target compounds 9a–t were evaluated against a panel of human tumor cell lines, including 
A-549 (lung carcinoma), MDA-MB-231 (triple-negative breast cancer), KB 
(nasopharyngeal carcinoma), and KBvin (vincristine resistant KB subline), using a 
sulforhodamine B colorimetric (SRB) assay with triplicate experiments. Topotecan (2) was 
used as a positive control and the antiproliferative activities of compounds are shown in 
Table 1. Except for compounds 9c and 9l, all target compounds exhibited significant in vitro 
antiproliferative activity against the four tested tumor cell lines, with IC50 values ranging 
from 0.055 to 0.84 μM, and were as or more potent than 2. Remarkably, all of the 
compounds were more potent than 2 (IC50, 0.40 μM) against the multidrug-resistant KBvin 
cell line, with 9e (IC50, 0.057 μM) and 9j (IC50, 0.072 μM) showing the greatest cytotoxicity 
against this cell line. Thus, spin-labeling of CPT at the C-20-hydroxyl position might 
overcome the MDR phenotype. As commonly found with prodrugs, esterification of the 
C-20-hydroxyl of CPT with different sulfonylamidine side chains led to somewhat 
decreased cytotoxic activity against A549, DU-145, and KB tumor cell lines in comparison 
to 2.19 This result is in agreement with our prior observations with C-20-substituted CPT 
derivatives as potent prodrugs.37 The IC50 values also revealed that the A-549 cell line was 
more sensitive than the other three cell lines to these compounds, which is consistent with 
the clinical behavior of other CPT derivatives.20
Furthermore, some preliminary SAR correlations were also observed for these spin-labeled 
20-sulfonylamidine CPT derivatives. As shown in Scheme 1, the modified groups included 
R1 on the amidine carbon, R2 on the sulfonyl moiety, and R3 as the nitroxide moiety. When 
the R2 and R3 substituents were kept constant and the R1 group in the sulfonylamidine was 
varied, hydrogen (9a) and methyl (9b) gave the best results compared with the larger alkyl 
groups in 9c (isopropyl), 9k (isobutyl), and 9l (sec-butyl), suggesting that small aliphatic 
chains appear to be the best R1 substituents for greater cytotoxic potency. Moreover, when 
the R1 group was fixed as hydrogen, R3 was fixed as a piperidinyl moiety, and the R2 group 
in the sulfonylamidine was varied, similar results were seen in the corresponding derivatives 
9d–j, 9n, and 9o, indicating that the substituent’s size is critical. Furthermore, the 
cytotoxicity of these compounds was distinctly correlated with the nitroxide moiety. Also, 
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the ring size and degree of unsaturation did not obviously affect the potency of the target 
compounds against three (A-549, MDA-MB-231, KB) of the four tested tumor cell lines, 
which was consistent with the literature.32 Overall, the results suggest that the cytotoxic 
potencies of our designed derivatives were dual controlled by altering the length of the 
sulfonylamidine arm as well as the size of the substituent group. The best antiproliferative 
activity was achieved only with an appropriate balance between flexibility and size, such as 
in 9e and 9j.
3. Conclusion
In summary, application of free radical compounds of the stable nitroxide type has become 
increasingly frequent in medicinal chemistry studies during recent years. In particular, 
design and synthesis of spin-labeled antitumor drugs using nitroxide groups as biological 
response modifiers have elicited widespread interest in cancer chemotherapy. As an 
extension to our studies on spin-labeled antitumor drugs, we designed and synthesized a 
series of novel 20-modified spin-labeled CPT derivatives, which were then evaluated for 
antiproliferative activities against four tumor cell lines (A-549, MDA-MB-231, KB, KBvin) 
by using a sulforhodamine B colorimetric assay. The cytotoxic results showed that most of 
the new spin-labeled compounds exhibited significant antiproliferative activities against four 
tumor cell lines. Notably, except for compounds 9c, 9k, and 9l, all compounds were more 
potent than 2 against multidrug-resistant KBvin cells. SAR analysis indicated that the size, 
electron density, and distribution of the substituents within the sulfonylamidine side chain 
are critical to the derivatives’ activity. These findings support our further optimization of 
CPT to develop potential spin-labeled CPT-derived anticancer drug candidates. Continuing 
studies to substantiate and improve activity profiles are underway in our laboratory and will 
be reported in due course.
4. Experimental section
4.1. General
All reagents and solvents were of reagent grade or purified according to standard methods 
before use. Analytical thin-layer chromatography (TLC) and preparative thin-layer 
chromatography (PTLC) were performed with silica gel plates using silica gel 60 GF254 
(Qingdao Haiyang Chemical Co., Ltd.). Melting points were taken on a Kofler melting point 
apparatus and are uncorrected. IR spectra were measured on a Nicolet 380 FT-IR 
spectrometer on neat samples placed between KBr plates. The EPR spectra were obtained 
with a Bruker A300 X-band EPR spectrometer. MS analyses were performed on ZAB-HS 
and Bruker Daltonics APEXII49e instruments. The starting CPT was isolated from the 
Chinese medicinal plant C. acuminata, and was purified before being used.3 The 
intermediate CPT-20-esters of N-Boc-amino acid derivatives 7 and their TFA salts 8 were 
synthesized according to our previous procedures.37
4.2. General synthetic procedure for compounds 9a–9t
Triethylamine (1.2 mmol) was added slowly to a suspension of the various TFA salts 8 (0.5 
mmol) in CH2Cl2 (35mL), and this mixture was stirred for 10 min when a clear solution was 
obtained. Under an N2 atmosphere, alkyne (0.5 mmol), sulfonylazide (0.6 mmol), and CuI 
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(0.05 mmol) were added into this reaction mixture at room temperature. After the reaction 
was completed, as monitored by TLC, the reaction mixture was diluted by adding CH2Cl2 (4 
mL) and aqueous NH4Cl solution (6 mL). The mixture was stirred for an additional 30 min 
and two layers were separated. The aqueous layer was extracted with CH2Cl2 (3 mL × 3). 
The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. 
The crude residue was purified by flash column chromatography with an appropriate eluting 
solvent system.
Compound 9a. Yield 70%; yellow orange solid; mp 133–134 °C; IR (KBr) ν (cm−1): 3432, 
2978, 2939, 1753, 1664, 1618, 1560, 1449, 1402, 1385 (NO·), 1273, 1147, 1094, 881, 761, 
669, 616, 556; Anal. Calcd for C41H46N5O9S: C, 62.74; H, 5.91; N, 8.92. Found: C, 62.70; 
H, 6.01; N, 8.87; EPR: g0=2.0064, An=14.62Gs (triplet peak in 1×10−4 M, DMF); MS-ESI 
m/z: 785.3 [M+H]+.
Compound 9b. Yield 67%; yellow orange solid; mp 118–121 °C; IR (KBr) ν (cm−1): 3433, 
2977, 2938, 1752, 1664, 1618, 1545, 1458, 1403, 1384 (NO·), 1273, 1145, 1090, 881, 787, 
724, 616, 555; Anal. Calcd for C42H48N5O9S: C, 63.14; H, 6.06; N, 8.77. Found: C, 63.10; 
H, 6.01; N, 8.90; EPR: g0=2.0060, An=14.62Gs (triplet peak in 1×10−4 M, DMF); MS-ESI 
m/z: 800.2 [M+2H]+.
Compound 9c. Yield 71%; yellow orange solid; mp 128–130 °C; IR (KBr) ν (cm−1): 3448, 
2975, 2930, 2873, 1751, 1666, 1618, 1561, 1546, 1439, 1402, 1385 (NO·), 1272, 1145, 
1091, 881, 670, 616, 555; Anal. Calcd for C44H52N5O9S: C, 63.90; H, 6.34; N, 8.47. Found: 
C, 64.03; H, 6.31; N, 8.56; EPR: g0=2.0061, An=14.62Gs (triplet peak in 1×10−4 M, DMF); 
MS-ESI m/z: 828.3 [M+2H]+.
Compound 9d. Yield 70%; yellow orange solid; mp 125–127 °C; IR (KBr) ν (cm−1): 3448, 
2974, 2929, 1752, 1655, 1618, 1560, 1508, 1402, 1385 (NO·) 1272, 1122, 881, 788, 670, 
617, 474; Anal. Calcd for C35H42N5O9S: C, 59.31; H, 5.97; N, 9.88. Found: C, 59.43; H, 
6.01; N, 8.79; EPR: g0=2.0066, An=14.62Gs (triplet peak in 1×10−4 M, DMF); MS-ESI m/z: 
731.3 [M+Na]+.
Compound 9e. Yield 64%; yellow orange solid; mp 124–126 °C; IR (KBr) ν (cm−1): 3431, 
2974, 2929, 1753, 1655, 1618, 1561, 1508, 1439, 1403, 1384 (NO·), 1270, 1233, 1118, 881, 
787, 758, 616, 475; Anal. Calcd for C36H44N5O9S: C, 59.82; H, 6.14; N, 9.69. Found: C, 
59.73; H, 6.08; N, 9.58; EPR: g0=2.0064, An=14.62Gs (triplet peak in 1×10−4 M, DMF); 
MS-ESI m/z: 745.4 [M+Na]+.
Compound 9f. Yield 66%; yellow orange solid; mp 123–125 °C; IR (KBr) ν (cm−1): 3423, 
2973, 2926, 2870, 1758, 1663, 1618, 1561, 1458, 1404, 1384 (NO·), 1267, 1234, 1181, 
1119, 881, 788, 763, 724, 669, 616; Anal. Calcd for C38H48N5O9S: C, 60.78; H, 6.44; N, 
9.33. Found: C, 60.89; H, 6.38; N, 9.50; EPR: g0=2.0060, An=14.62Gs (triplet peak in 
1×10−4 M, DMF); MS-ESI m/z: 773.4 [M+Na]+.
Compound 9g. Yield 68%; yellow orange solid; mp 142–144 °C; IR (KBr) ν (cm−1): 3423, 
2975, 2931, 1753, 1664, 1618, 1560, 1499, 1458, 1403, 1384 (NO·), 1257, 1146, 1094, 881, 
854, 805, 762, 724, 696, 614, 555; Anal. Calcd for C41H46N5O10S: C, 61.49; H, 5.79; N, 
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8.74. Found: C, 61.54; H, 5.86; N, 8.67; EPR: g0=2.0062, An=14.62Gs (triplet peak in 
1×10−4 M, DMF); MS-ESI m/z: 823.2 [M+Na]+.
Compound 9h. Yield 73%; yellow orange solid; mp 144–146 °C; IR (KBr) ν (cm−1): 3423, 
2975, 2934, 1753, 1666, 1618, 1561, 1508, 1458, 1402, 1385 (NO·), 1272, 1234, 1149, 
1095, 881, 762, 726, 618, 483; Anal. Calcd for C40H43ClN5O9S: C, 59.66; H, 5.38; N, 8.70. 
Found: C, 59.70; H, 5.45; N, 8.57; EPR: g0=2.0064, An=14.62Gs (triplet peak in 1×10−4 M, 
DMF); MS-ESI m/z: 806.3 [M+2H]+.
Compound 9i. Yield 64%; yellow orange solid; mp 105–107 °C; IR (KBr) ν (cm−1): 3422, 
2975, 2930, 2871, 1753, 1663, 1593, 1560, 1496, 1458, 1403, 1383 (NO·), 1272, 1236, 
1147, 1091, 1050, 880, 839, 764, 669, 616, 555; Anal. Calcd for C40H43FN5O9S: C, 60.90; 
H, 5.49; N, 8.88. Found: C, 61.01; H, 5.55; N, 8.49; EPR: g0=2.0066, An=14.62Gs (triplet 
peak in 1×10−4 M, DMF); MS-ESI m/z: 790.3 [M+2H]+.
Compound 9j. Yield 68%; yellow orange solid; mp 135–137 °C; IR (KBr) ν (cm−1): 3393, 
2973, 2901, 1757, 1663, 1606, 1560, 1529, 1450, 1404, 1384 (NO·), 1351, 1223, 1150, 
1081, 1050, 880, 747, 617, 464; Anal. Calcd for C40H43N6O11S: C, 58.89; H, 5.31; N, 
10.30. Found: C, 58.94; H, 5.45; N, 10.25; EPR: g0=2.0060, An=14.62Gs (triplet peak in 
1×10−4 M, DMF); MS-ESI m/z: 817.4 [M+2H]+.
Compound 9k. Yield 62%; yellow orange solid; mp 120–122 °C; IR (KBr) ν (cm−1): 3385, 
2973, 2900, 1750, 1663, 1618, 1549, 1452, 1404, 1384 (NO·), 1272, 1234, 1146, 1087, 
1050, 880, 814, 763, 689, 618, 556; Anal. Calcd for C45H54N5O9S: C, 64.27; H, 6.47; N, 
8.33. Found: C, 64.38; H, 6.56; N, 8.21; EPR: g0=2.0062, An=14.62Gs (triplet peak in 
1×10−4 M, DMF); MS-ESI m/z: 842.4 [M+2H]+.
Compound 9l. Yield 70%; yellow orange solid; mp 122–124 °C; IR (KBr) ν (cm−1): 3401, 
2973, 2935, 2873, 1751, 1664, 1604, 1545, 1458, 1403, 1384 (NO·), 1273, 1147, 1091, 
1051, 881, 815, 669, 617, 556; Anal. Calcd for C45H54N5O9S: C, 64.27; H, 6.47; N, 8.33. 
Found: C, 64.38; H, 6.56; N, 8.21; EPR: g0=2.0064, An=14.62Gs (triplet peak in 1×10−4 M, 
DMF); MS-ESI m/z: 842.4 [M+2H]+.
Compound 9m. Yield 68%; yellow orange solid; mp 112–114 °C; IR (KBr) ν (cm−1): 3402, 
2974, 2901, 1751, 1655, 1618, 1560, 1544, 1450, 1405, 1384 (NO·), 1250, 1079, 1066, 
1050, 881, 701, 617; Anal. Calcd for C48H52N5O9S: C, 65.89; H, 5.99; N, 8.00. Found: C, 
65.98; H, 6.12; N, 8.06; EPR: g0=2.0066, An=14.62Gs (triplet peak in 1×10−4 M, DMF); 
MS-ESI m/z: 876.4 [M+2H]+.
Compound 9n. Yield 59%; yellow orange solid; mp 141–143 °C; IR (KBr) ν (cm−1): 3411, 
2974, 2932, 1754, 1662, 1604, 1560, 1458, 1403, 1384 (NO·), 1272, 1236, 1127,1082, 1050, 
880, 787, 724, 688, 619, 555, 480; Anal. Calcd for C44H46N5O9S: C, 64.37; H, 5.65; N, 
8.53. Found: C, 64.30; H, 5.54; N, 8.46; EPR: g0=2.0062, An=14.62Gs (triplet peak in 
1×10−4 M, DMF); MS-ESI m/z: 822.4 [M+2H]+.
Compound 9o. Yield 67%; yellow orange solid; mp 136–138 °C; IR (KBr) ν (cm−1): 3423, 
2975, 2938, 1753, 1663, 1617, 1560, 1458, 1404, 1384 (NO·), 1292, 1234, 1143, 1093, 
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1015, 881, 762, 724, 669, 618, 592; Anal. Calcd for C38H42N5O9S2: C, 58.75; H, 5.45; N, 
9.01. Found: C, 58.65; H, 5.38; N, 9.21; EPR: g0=2.0066, An=14.62Gs (triplet peak in 
1×10−4 M, DMF); MS-ESI m/z:878.3 [M+2H]+.
Compound 9p. Yield 75%; yellow orange solid; mp 105–107 °C; IR (KBr) ν (cm−1): 3423, 
2974, 2928, 1756, 1663, 1601, 1560, 1457, 1403, 1384 (NO·), 1273, 1236, 1177, 1147, 
1094, 1050, 920, 881, 818, 763, 695, 615, 556, 480; Anal. Calcd for C42H48N5O9S: C, 
63.14; H, 6.06; N, 8.77. Found: C, 63.04; H, 6.19; N, 8.92; EPR: g0=2.0060, An=14.62Gs 
(triplet peak in 1×10−4 M, DMF); MS-ESI m/z: 800.4 [M+2H]+.
Compound 9q. Yield 65%; light yellow solid; mp 121–123 °C; IR (KBr) ν (cm−1): 3415, 
2973, 2931, 2871, 1757, 1663, 1603, 1561, 1442, 1402, 1384 (NO·), 1256, 1190, 1120, 
1084, 1049, 977, 881, 787, 724, 613, 562, 475; Anal. Calcd for C35H40N5O9S: C, 59.48; H, 
5.70; N, 9.91. Found: C, 59.56; H, 5.63; N, 10.02; EPR: g0=2.0058, An=14.76Gs (triplet 
peak in 1×10−4 M, DMF); MS-ESI m/z: 729.3 [M+Na]+;
Compound 9r. Yield 61%; light yellow solid; mp 110–112 °C; IR (KBr) ν (cm−1): 3422, 
2974, 2929, 1752, 1655, 1603, 1560, 1458, 1439, 1384 (NO·), 1273, 1147, 1093, 1050, 881, 
724, 695, 616, 556; Anal. Calcd for C41H44N5O9S: C, 62.90; H, 5.66; N, 8.95. Found: C, 
63.00; H, 5.53; N, 9.01; EPR: g0=2.0055, An=14.76Gs (triplet peak in 1×10−4 M, DMF); 
MS-ESI m/z: 805.4 [M+Na]+.
Compound 9s. Yield 70%; light yellow solid; mp 120–122 °C; IR (KBr) ν (cm−1): 3415, 
2974, 2929, 1756, 1664, 1598, 1560, 1499, 1458, 1403, 1384 (NO·), 1258, 1146, 1094, 
1051, 881, 836, 805, 725, 697, 614, 567; Anal. Calcd for C41H44N5O10S: C, 61.64; H, 5.55; 
N, 8.77. Found: C, 61.81; H, 5.42; N, 8.85; EPR: g0=2.0058, An=14.76Gs (triplet peak in 
1×10−4 M, DMF); MS-ESI m/z: 800.3 [M+2H]+.
Compound 9t. Yield 69%; light yellow solid; mp 103–105 °C; IR (KBr) ν (cm−1): 3423, 
2974, 2927, 1753, 1663, 1592, 1560, 1495, 1458, 1403, 1384 (NO·), 1279, 1234, 1186, 
1148, 1091, 880, 839, 763, 724, 699, 613, 554, 481; Anal. Calcd for C40H41FN5O9S: C, 
61.06; H, 5.25; N, 8.90. Found: C, 61.21; H, 5.15; N, 9.02; EPR: g0=2.0055, An=14.76Gs 
(triplet peak in 1×10−4 M, DMF); MS-ESI m/z: 809.4 [M+Na]+.
4.3. Cytotoxicity assays
The human tumor cell lines, A549 (lung carcinoma), MDA-MB-231 (triple-negative breast 
cancer), KB (originally isolated from epidermoid carcinoma of the nasopharynx), and KBvin 
(vincristine-resistant KB subline), were obtained from the Lineberger Comprehensive 
Cancer Center (UNC-CH) or from ATCC (Manassas, VA), except KBvin, which was a 
generous gift of Professor Y.-C. Cheng (Yale University). All cell lines were maintained and 
assayed in RPMI-1640 medium containing 2 mM L-glutamine and 25 mM HEPES 
(HyClone), supplemented with 10% heat-inactivated fetal bovine serum (HyClone), 100 
μg/mL streptomycin, 100 IU/mL penicillin, and 0.25 μg/mL amphotericin B (Cellgro) in a 
humidified atmosphere containing 5% CO2 in air. Cytotoxic activity was determined by the 
sulforhodamine B (SRB) colorimetric assay as previously described.37 In brief, the cells 
(4.0–7.5 × 103 cells/well) were seeded in 96-well plates filled with various concentrations of 
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samples in culture medium, and cultured for 72 h at 37 °C with 5% CO2 in air. At the end of 
the exposure period, the surviving cells were fixed in10% trichloroacetic acid for 30 min at 
room temperature followed by staining with 0.04% SRB (Sigma Chemical Co.) for 30 min. 
The protein-bound SRB was solubilized with 10 mM Tris-base and the absorbance of SRB 
was measured at 515 nm on a ELx800 Microplate Reader (Bio-Tek Instruments, Winooski, 
VT) operated by Gen5 software. All results were representative of three or more 
experiments and expressed as an average with standard deviation (SD).
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Structures of camptothecin (1), topotecan (2), irinotecan (3), gimatecan (4), CKD-602 (5), 
and BNP-1350 (6).
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Synthesis of target compounds 9a–9t.
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Table 1
In vitro cytotoxicity of compounds 9a–t against four human tumor cell lines.a
Entry
IC50(μM) (Average ± SD)b
A-549 MDA-MB-231 KB KBvin
9a 0.076± 0.026 0.45 ± 0.10 0.21± 0.016 0.11± 0.010
9b 0.45 ± 0.0067 0.53 ± 0.0099 0.56 ± 0.0086 0.25± 0.080
9c >1 >1 >1 >1
9d 0.059± 0.021 0.11± 0.024 0.071± 0.030 0.090 ± 0.037
9e 0.055± 0.013 0.080 ± 0.0077 0.059± 0.0015 0.057± 0.014
9f 0.062± 0.015 0.23 ± 0.12 0.075 ± 0.011 0.095 ± 0.0094
9g 0.081± 0.010 0.27± 0.12 0.11 ± 0.0011 0.096± 0.0056
9h 0.063± 0.015 0.19± 0.076 0.073± 0.0080 0.084± 0.013
9i 0.086 ± 0.0065 0.27 ± 0.090 0.12 ± 0.028 0.10 ± 0.0035
9j 0.058± 0.012 0.10 ± 0.0024 0.059 ± 0.020 0.072 ± 0.014
9k 0.61 ± 0.0057 0.84 ± 0.0016 0.70 ± 0.021 0.74± 0.031
9l >1 >1 >1 >1
9m 0.17± 0.087 0.50± 0.097 0.31± 0.18 0.10± 0.0016
9n 0.48± 0.022 0.61± 0.0066 0.58 ± 0.013 0.33± 0.066
9o 0.063± 0.0021 0.11± 0.010 0.063 ± 0.026 0.083± 0.022
9p 0.062± 0.0038 0.091± 0.0025 0.080± 0.020 0.084± 0.011
9q 0.0629 ± 0.0061 0.1027 ± 0.0027 0.0823 ± 0.0327 0.0834± 0.0207
9r 0.074 ± 0.0054 0.12± 0.0029 0.091± 0.013 0.094± 0.0021
9s 0.090± 0.0040 0.18 ± 0.0013 0.13± 0.038 0.15 ± 0.0059
9t 0.077± 0.0006 0.14± 0.0033 0.12 ± 0.026 0.095± 0.0013
2 0.045± 0.0004 0.10 ± 0.0055 0.063± 0.0042 0.40 ± 0.021
a
A549 (lung carcinoma), MDA-MB-231 (triple-negative breast cancer), KB (originally isolated from epidermoid carcinoma of the nasopharynx), 
KBvin (vincristine-resistant KB subline).
b
Each assay was performed in triplicate with duplicated sample, and averaged IC50 (μM) values were expressed with standard deviation (SD).
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